PCRC_A091802

Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC).

This phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Key Eligibility:
• Biopsy-proven advanced cutaneous squamous cell carcinoma.
• The patient must have at least one lesion that is measurable disease.
• Patients cannot have received treatment with radiation or chemotherapy including another investigational agent within 2 weeks of registration.
• If patient received major surgery, they must have recovered adequately from the toxicity and or complications from the intervention prior to starting therapy.
Phase II
NCT03944941
Oncology
Cutaneous (skin)
Alison Conlin, M.D.
Alliance
Chris Fountain

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.